Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Evelyne, Kohli"'
Autor:
Mathieu Guerriaud, Evelyne Kohli
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Many RNA-based drugs, both vaccines and non-vaccines, are under development or even approved. They include coding mRNAs and non-coding (nc) RNAs among them antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), micro-RNAs (miRNAs), small
Externí odkaz:
https://doaj.org/article/02be55920ae44568a1cd8140cb9c18c5
Autor:
Fangmin Wang, Wenwen Shen, Yujia Cai, Xin Zhang, Han Du, Miaojun Lai, Huifen Liu, Evelyne Kohli, Wenhua Zhou
Publikováno v:
Frontiers in Psychiatry, Vol 13 (2022)
Buprenorphine, which has been approved for the treatment of opioid dependence, reduces cocaine consumption by co-activating μ-opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. However, the role of buprenorphine in methamphetamine
Externí odkaz:
https://doaj.org/article/71e67d2c6eab429582430652f22d2b95
Autor:
Killian Chaumonnot, Sophie Masson, Hugo Sikner, Alexanne Bouchard, Valentin Baverel, Pierre-Simon Bellaye, Bertrand Collin, Carmen Garrido, Evelyne Kohli
Publikováno v:
Cell Death and Disease, Vol 12, Iss 1, Pp 1-15 (2021)
Abstract The role of GRP94, an endoplasmic reticulum (ER) stress protein with both pro- and anti-inflammatory functions, has not been investigated in macrophages during ER stress, whereas ER stress has been reported in many diseases involving macroph
Externí odkaz:
https://doaj.org/article/c293ab5a1df347eea241df8e1302f7d4
Autor:
Alexandre M. M. Dias, Alan Courteau, Pierre-Simon Bellaye, Evelyne Kohli, Alexandra Oudot, Pierre-Emmanuel Doulain, Camille Petitot, Paul-Michael Walker, Richard Decréau, Bertrand Collin
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2388 (2022)
Cancer immunotherapy has tremendous promise, but it has yet to be clinically applied in a wider variety of tumor situations. Many therapeutic combinations are envisaged to improve their effectiveness. In this way, strategies capable of inducing immun
Externí odkaz:
https://doaj.org/article/6c803b16a29346f3a4fe815d80aa4742
Autor:
Alexanne Bouchard, Hugo Sikner, Valentin Baverel, Anaïs-Rachel Garnier, Marie Monterrat, Mathieu Moreau, Emeric Limagne, Carmen Garrido, Evelyne Kohli, Bertrand Collin, Pierre-Simon Bellaye
Publikováno v:
Cells, Vol 10, Iss 12, p 3393 (2021)
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancers and is not eligible for hormone and anti-HER2 therapies. Identifying therapeutic targets and associated biomarkers in TNBC is a clinical challenge to improve patien
Externí odkaz:
https://doaj.org/article/1e79ea499e7148339de2587741d4de81
Publikováno v:
Vaccines, Vol 9, Iss 10, p 1140 (2021)
Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination regimens including a first administration of a viral vector-based vacc
Externí odkaz:
https://doaj.org/article/f2b159a9bf7f4e71b7931cd8d1f0290d
Publikováno v:
Biology, Vol 10, Iss 9, p 836 (2021)
Glycoprotein-A repetitions predominant (GARP) is the docking receptor for latent transforming growth factor (LTGF-β) and promotes its activation. In cancer, increased GARP expression has been found in many types of cancer. GARP is expressed by regul
Externí odkaz:
https://doaj.org/article/d54748d038d148a7bddb36b99959b7c6
Publikováno v:
Vaccines, Vol 9, Iss 8, p 883 (2021)
Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine
Externí odkaz:
https://doaj.org/article/3d294ffe9b824e7b943339c29dbd09bf
Autor:
Evelyne, Kohli, Frédéric, Huet
Publikováno v:
Virologie (Montrouge, France). 15(3)
Group A rotavirus is the most common cause of severe gastroenteritis in young children globally, estimated to cause approximately 500,000 deaths each year, mainly in low-income countries. Two oral vaccines are currently licensed, a monovalent attenua
Autor:
Mathieu Moreau, Emeric Limagne, Hugo Sikner, Marie Monterrat, Evelyne Kohli, Valentin Baverel, Pierre-Simon Bellaye, Bertrand Collin, Carmen Garrido, Alexanne Bouchard, Anaïs-Rachel Garnier
Publikováno v:
Cells, Vol 10, Iss 3393, p 3393 (2021)
Cells; Volume 10; Issue 12; Pages: 3393
Cells; Volume 10; Issue 12; Pages: 3393
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancers and is not eligible for hormone and anti-HER2 therapies. Identifying therapeutic targets and associated biomarkers in TNBC is a clinical challenge to improve patien